Durect Corporation - Asset Resilience Ratio
Durect Corporation (DRRX) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Durect Corporation to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Durect Corporation's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see DRRX total assets.
Liquid Assets Composition Over Time
This chart breaks down Durect Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore DRRX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Durect Corporation maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Durect Corporation Industry Peers by Asset Resilience Ratio
Compare Durect Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Durect Corporation (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Durect Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.32% | $792.00K | $18.35 Million | +1.48pp |
| 2023-12-31 | 2.83% | $1.28 Million | $45.19 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $60.10 Million | -- |
| 2021-12-31 | 21.70% | $19.97 Million | $91.99 Million | -3.97pp |
| 2020-12-31 | 25.68% | $19.42 Million | $75.64 Million | -8.91pp |
| 2019-12-31 | 34.58% | $29.75 Million | $86.02 Million | +29.24pp |
| 2018-12-31 | 5.34% | $2.67 Million | $50.00 Million | -8.56pp |
| 2017-12-31 | 13.90% | $7.38 Million | $53.11 Million | -34.48pp |
| 2016-12-31 | 48.39% | $19.60 Million | $40.51 Million | -6.04pp |
| 2015-12-31 | 54.43% | $25.46 Million | $46.77 Million | -5.50pp |
| 2014-12-31 | 59.93% | $30.02 Million | $50.08 Million | +28.69pp |
| 2013-12-31 | 31.24% | $12.75 Million | $40.82 Million | -6.50pp |
| 2012-12-31 | 37.74% | $17.34 Million | $45.94 Million | -2.71pp |
| 2011-12-31 | 40.45% | $19.90 Million | $49.20 Million | -11.46pp |
| 2010-12-31 | 51.91% | $35.07 Million | $67.56 Million | -4.55pp |
| 2009-12-31 | 56.46% | $32.83 Million | $58.15 Million | +28.64pp |
| 2008-12-31 | 27.83% | $20.84 Million | $74.87 Million | +4.37pp |
| 2007-12-31 | 23.46% | $19.71 Million | $84.02 Million | -4.15pp |
| 2006-12-31 | 27.61% | $28.30 Million | $102.48 Million | +12.26pp |
| 2005-12-31 | 15.35% | $18.02 Million | $117.41 Million | -10.12pp |
| 2004-12-31 | 25.47% | $21.77 Million | $85.47 Million | -9.68pp |
| 2003-12-31 | 35.15% | $39.51 Million | $112.41 Million | -4.20pp |
| 2002-12-31 | 39.35% | $28.71 Million | $72.97 Million | -1.26pp |
| 2001-12-31 | 40.60% | $42.61 Million | $104.94 Million | -7.26pp |
| 2000-12-31 | 47.86% | $57.73 Million | $120.61 Million | -8.83pp |
| 1999-12-31 | 56.69% | $12.73 Million | $22.46 Million | -- |
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more